



# COUNTAGEN

ADVANCING CELL & GENE THERAPY SAFETY

**Felix Neumann**

CEO & Co-founder

[felix@countagen.com](mailto:felix@countagen.com)


September 30, 2025

# Future of Healthcare: Cell & Gene Therapies



2,200+ ongoing gene therapy programs, **but safety remains a major concern**

CRISPR-Cas



On-target


Off-target

**Gene editing requires thorough analysis from research to post-surveillance**

# Future of Healthcare: Cell & Gene Therapies

2,200+ ongoing gene therapy programs, **but safety remains a major concern**

CRISPR-Cas




**Gene editing requires thorough analysis from research to post-surveillance**

**FDA mandates comprehensive on- & off-target validation**



**Gold standard platform to satisfy all development stages is missing**

# Countagen solves the problem with a novel PCR-free methodology



**Proven technology through validation across segments & shared white papers**

# Building a complete technology suite to serve gene editing needs



## Imaging-Based

### GeneAbacus

#### Targeted Validation

- Consumable reagent kit
- In-house analysis
- Early access customers

## Sequencing-Based

### LockSeq

#### Comprehensive Analysis

- Sample-to-report
- Full service
- Pilot collaborations




Memorial Sloan Kettering  
Cancer Center



UNIVERSITÄTS  
FREIBURG KLINIKUM

# Rapidly growing billion € opportunity




## Regulatory tailwinds create mandatory demand

# World-class team & assets

## Founder team



**Mats Nilsson**  
Professor at Stockholm  
University & Wellcome  
Sanger



**Mårten Winge**  
Serial Entrepreneur



**Malte Kuhnemund**  
R&D Director at 10X  
Genomics



**Iván Hernández-Neuta**  
CSO at Countagen



**Felix Neumann**  
CEO at Countagen

Countagen

## Scientific Advisors



**Sören Turan**  
Scientist at Bayer  
Pharmaceuticals



**Bernhard Schmierer**  
Head at the CRISPR  
Functional Genomics Unit



## Strong Intellectual Property

Probing & Signal Generation	Readout	Data & Technology
<p><b>Gene editing analysis methods with padlocks and RCA</b></p> <p>GB2604872B<sup>1</sup> P91668GB<sup>4</sup></p>	<p><b>Methods and devices for single molecule DNA counting</b></p> <p>WO2020212531A1<sup>2</sup> WO2023075663A1<sup>3</sup></p>	<p>Proprietary Software</p> <p>Market Intelligence &amp; Network</p> <p>Unique Tech Know-How/Expertise</p>

- (1) National phase: Seeking worldwide protection. **Granted in UK.**  
 (2) National phase: Seeking protection in Europe. **Granted in US.**

- (3) National phase: Seeking worldwide protection.  
 (4) Priority application filed in UK (Dec 2024).



# Investment Opportunity

## €2M to Capture the US & EU Market

- 50% - LockSeq platform optimization & service establishment
- 20% - Market entry & expansion (US + Europe simultaneously)
- 15% - GeneAbacus integration & partnership
- 15% - Team growth & regulatory compliance

## Key Milestones

- 2025: LockSeq KOL endorsement
- 2026: LockSeq service pilots; GeneAbacus partnership; €1.5M ARR
- 2027: €10M ARR; established player for comprehensive on & off-target validation

**Our vision is to make Countagen the gold standard  
for cell & gene editing safety assessment**





# COUNTAGEN

## Let's Connect!

**Iván Hernández, PhD**

CSO & Co-founder

[ivan@countagen.com](mailto:ivan@countagen.com)

+46 722 691 740

**Felix Neumann, PhD**

CEO & Co-founder

[felix@countagen.com](mailto:felix@countagen.com)

+46 765 592 107

Countagen AB

Nobels väg 16

Stockholm, Sweden

[www.countagen.com](http://www.countagen.com)